Immunohistochemistry in Cancer Diagnostics in West Africa:Current Applications, Challenges, and Future Prospects

Authors

Keywords:

Automated Platforms, Cancer Diagnostics, Immunohistochemistry, Manual Platforms, Pathology Infrastructure, West Africa

Abstract

Immunohistochemistry (IHC) is a vital diagnostic tool in cancer pathology, enabling precise tumour classification, prognostication, and treatment stratification. However, its implementation in West Africa is still evolving, constrained by infrastructural, technical, and financial barriers. This study was set out to evaluate the current state of IHC use in cancer diagnostics in West Africa, outline key challenges, highlight regional and global practices, and explore prospects and policy recommendations. This review synthesises data from peer-reviewed publications, regional cancer registries, and institutional reports from 2018 to 2024. It includes global benchmarks, Sub-Saharan African, West African, and Nigerian data sources. IHC is available in major tertiary hospitals across Nigeria, Ghana, and Senegal, but remains limited in rural and secondary facilities. While its use in breast, prostate, and lymphoid malignancies has improved, key gaps include a lack of trained personnel, reagent stock-outs, and the absence of automated platforms. Regional disparities persist, with coverage favouring urban academic centres. Scaling up IHC in West Africa requires investment in infrastructure, training, public-private partnerships, and integration into national cancer control strategies. The need for standardised protocols and digital pathology is also urgent to enhance diagnostic precision.

Author Biographies

  • Gbaa ZL, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

  • Ojo BA, Benue State University

    Department of Histopathology, Benue State University Teaching Hospital, Makurdi, Nigeria.

  • Uko AF, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

  • Amina AJ, Federal University of Health Sciences, Otukpo

    Department of Surgery, Federal University of Health Sciences, Otukpo, Nigeria.

  • Inienger DR, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

  • Unande HM, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

  • Kawen PT, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

  • Gbaa FA, Benue State University

    Department of Surgery, College of Health Sciences, Benue State University, Makurdi, Nigeria.

References

1. Ramos-Vara JA. Immunohistochemistry: an overview. Vet Pathol. 2005;42(1):1–16. doi:10.1354/vp.42-1-1.

2. Dabbs DJ. Diagnostic Immunohistochemistry. 4th ed. Philadelphia, PA: Elsevier; 2014.

3. Prasad S, Gupta SC, Tyagi AK. Significance of immunohistochemistry in breast cancer. World J Cancer Res. 2015;2(1):1–10. PMCID: PMC4127609.

4. Weiss LM, Chu P. Immunohistochemical studies of metastatic carcinomas. In: Sternberg SS, Antonioli DA, Carter D, Mills SE, Oberman HA, editors. Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 45–66.

5. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.

6. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–64. doi:10.1093/jnci/djr393

7. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signalling axis. J Clin Oncol. 2005;23(33):8286–91. doi:10.1200/JCO.2005.03.121

8. Chetty R, Govender D. Immunohistochemistry in diagnostic pathology of infectious diseases. Arch Pathol Lab Med. 2020;144(7):851–60. doi:10.5858/arpa.2019-0394-RA

9. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

10. Jedy-Agba E, Oga E, Odutola M, Abdullahi YM, Popoola A, Balogun O, et al. Cancer incidence in Nigeria: A report from population-based cancer registries. Cancer Epidemiol. 2020; 67:101795.

11. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

12. Alatise OI, Schrauzer T, Adepoju A, Lawal OO, Okunade KS, Nwankwo KC, et al. Cancer care in Nigeria: Need for a comprehensive approach. Lancet Oncol. 2020;21(8): e342–50.

13. Carter JM, Ehinger M, Greipp PT, Vrana JA, Halling KC, Jenkins SM, et al. Immunohistochemistry in diagnostic pathology: advances and clinical applications. Arch Pathol Lab Med. 2021;145(4):452–62.

14. Tavassoli FA, Devilee P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.

15. World Health Organisation. Guide to Cancer Early Diagnosis. Geneva: WHO; 2020.

16. Patel K, Strother R M, Ndiangui F, Chumba D, Jacobson W, Dodson C, et al (2016). Development of immunohistochemistry services for cancer care in western Kenya: Implications for low- and middle-income countries. Afr J of Lab Med. 2016;5(1), 187. https://doi.org/10.4102/ajlm.v5i1.187

17. Batta H, Dogo D, Ekanem VJ, Saidu Y, Musa AB, Okeke EN, et al. Diagnostic utility and limitations of immunohistochemistry in Nigeria. Niger J Clin Pract. 2022;25(3):345–52.

18. Thomas JO. Histopathology in Nigeria: The challenges. Niger Med J. 2020;61(3):118–22.

19. Orakwe JC, Okonkwo CA, Nwaogu IC, Udeh CM, Onwukeme K, Agboeze J, et al. Status and patterns of immunohistochemistry in Nigerian tertiary hospitals: A cross-sectional analysis. Afr J Lab Med. 2023;12(1):a1598.

20. Akinwale OO, Nwankwo KC, Adesina A, Ogun GO, Adebamowo CA, Salako O, et al. Immunohistochemistry and cancer diagnostics in West Africa: A multicentre review. West Afr J Med. 2021;38(4):320–6.

21. Babalola EO, Ojo OS, Ibrahim M, Aina OO, Olowu AO, Afolabi AO, et al. Breast cancer molecular subtyping using IHC in Ibadan, Nigeria. Afr Health Sci. 2021;21(1):103–10.

22. Muwonge R, Swaminathan R, Sankaranarayanan R. Cancer control in developing countries: Implementation of the WHO guidelines. Int J Cancer. 2018;143(6):1333–9.

23. Ghartey FN, Agyeman-Yeboah J, Tetteh DA, Boamah I, Owusu-Afriyie O, Oppong J, et al. Histopathologic patterns of cancers in Ghana: A 5-year retrospective review. Ghana Med J. 2020;54(2):79–85.

24. Fall PA, Cissé ML, Seck B, Diagne M, Toure A, Diallo A, et al. Diagnostic delay in cancer care in Senegal: Role of pathology services. Pan Afr Med J. 2021; 39:203.

25. Federal Ministry of Health (Nigeria). National Cancer Control Plan (2018–2022). Abuja: FMOH; 2022.

26. Ghana Ministry of Health. National Strategy for Cancer Control in Ghana (2020–2024). Accra: MOH; 2020.

27. Faduyile FA, Soyemi SS, Akinola OI, Idowu AO, Obafemi OT, Odukoya O, et al. Human resource gaps in Nigerian pathology laboratories. Ann Trop Pathol. 2020;11(2):61–6.

28. Nwogu CM, Anyanwu S, Irekpita E, Okonkwo UC, Chidebe RC, Oduyebo O, et al. Fixation and processing challenges in IHC: An experience from Nigeria. Niger J Surg Sci. 2020;10(2):61–4.

29. Tshimwanga TM, Ngoyi JB, Ngoma T, Lubinga SJ, Mbuyi-Muamba JM, et al. The role of IHC in breast cancer diagnostics in East and Southern Africa. Afr J Med Med Sci. 2021;50(3):291–6.

30. Adewoyin AS, Olowoselu FO. The promise and perils of IHC in Nigeria's oncology ecosystem. Afr J Lab Med. 2023;12(1):a1573.

31. Wright AJ, Thomas JD. Regional disparities in immunodiagnostics in Africa. J Glob Oncol. 2020;6(3):520–9.

32. Pathologists Overseas. Supporting African labs in IHC development: Impact report 2021. [Internet]. 2021 [cited 2025 Jul 14]. Available from: https://www.pathologistsoverseas. org. Accessed Date 16 July 2025?

33. World Health Organisation, Regional Office for Africa. National Cancer Control Plans: Status in the WHO African Region. Brazzaville: WHO AFRO; 2 021. ? URL, Accessed Date 14th July 2025

34. African Cancer Registry Network (AFCRN). IHC utilisation and data harmonisation in member registries. AFCRN Bull. 2022;10(1):3–8.

35. Roche Diagnostics. Africa IHC Access Initiative: 2023 Report. [Internet]. 2023 [cited 2025 Jul 14]. Available from: https://www.roche.com/africa-ihc. Access Date 2025 July 14

36. Vigdorovits, A., Köteles, M. M., Olteanu, G., & Pop, O. (2022). Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems. Cancers, 15(23), 5692. https://doi.org/10.3390/cancers15235692

37. Ekenze SO, Okoro CI, Agwu NP, Okpara OC, Nwagboso EC, Onuoka CI, et al. Delays to cancer care and outcomes in a low-resource setting: The experience from Enugu, South-East Nigeria. J Cancer Epidemiol. 2022; 2022:9809059. doi:10.1155/2022/9809059.

38. WHO Regional Office for Africa. National Cancer Control Plans: Status in the WHO African Region. Brazzaville: WHO AFRO; 2021.Available from: https://www.afro.who.int

39. Pathologists Overseas. Supporting African labs in IHC development: Impact report 2021. [Internet]. ?URL, Accessed Date 27 August 2025.Available from:https://www.pathologistsoverseas.org

40. Salako O, Ojeniran MA, Fatiregun OA, Ali-Gombe A, Alabi O, Ayandipo O, et al. Access to oncology services in Nigeria: The diagnostic bottleneck. BMC Health Serv Res. 2020;20(1):65. https://doi.org/10.1186/s12913-020-4892-4

Downloads

Published

2025-08-31

Issue

Vol. 6 No. 3 (2025): Assessment of the usefulness of maternal serum beta-human chorionic gonadotrophin as predictive marker for pre eclampsia and poor clinical neonatal outcome

Section

Articles